Report Library
All Reports
2015 Post-AAIC KOL Interview
August 31, 2015
Following the 2015 Alzheimer's Association International Conference (AAIC), we interviewed an Alzheimer's Disease expert on his opinion of
the data presentations and the future of Alzheimer's Disease treatment. A BioMedTracker Scientific Analyst was also at the meeting, and we
will shortly release a full event-driven, AAIC post-report.
Highlights
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
Highlights
- KOL thought the overall tone of the meeting was more positive than prior years with a renewed vigor around amyloid targeted therapy.
- Early stage agents that looked promising were NPT-088 (Neurophage) and TRV 101 (Treventis).
- Solanezumab had positive data from extension study of EXPEDITION 1 and 2, but the interpretation of the data was a stretch (LLY).
- KOL didn't believe the 6mg dose of aducanumab was all that far off the mark and expects Phase III trial to move forward with doses lower than 10mg to avoid ARIA events (BIIB).
- BACE Inhibitor data will not be the definitive story for amyloid targeted compounds (MRK).
- 5-HT6 targeted therapies have a reasonable shot but not expected to garner much support from physicians and families due to very modest improvements (AXON, Lundbeck).
- Enrollment of trials is easier for Nuedexta and pimavanserin since there are no black box warnings in elderly patients as there are for antipsychotics (Otsuka, ACAD).
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: |
Alzheimer's Disease (AD)
Alzheimer's Disease - Imaging Mild Cognitive Impairment (MCI) |
Additional Resources: